ストックスクリーナーアプリを入手
11.97
13.40%
1.37
Artiva Biotherapeutics Inc (ARTV) 最新ニュース
Why Artiva Bio (ARTV) could be the turning point you've been waiting for (Gains) 2026-05-05Technical Analysis - Newser
Artiva Biotherapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
Artiva Biotherapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Executive pay and ownership detailed in Artiva Biotherapeutics (NASDAQ: ARTV) 10-K/A - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Deep B-Cell Depletion: The Next Wave In Autoimmune Diseases With Artiva's AlloNK In Focus - RTTNews
Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham - MarketBeat
ARTV: Advancing scalable NK cell therapy for RA, targeting deep, durable responses in refractory patients - TradingView
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Whale Trades: Is Blend Labs Inc backed by strong institutional buying2026 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm
Can Artiva Bio (ARTV) Stock Reach New Highs | Price at $6.37, Down 4.50%Crowd Breakout Signals - Newser
Should I Buy Artiva Bio (ARTV) Stock Now | Price at $7.29, Up 8.16%Expert Stock Picks - Newser
ARTV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Hold at Wall Street Zen - MarketBeat
ARTV Stock Analysis: Bearish Pressure Amid Market Decline - Newser
Artiva Biotherapeutics Inc. (ARTV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What are hedge funds doing with Artiva Bio (ARTV) Stock | Price at $6.74, Down 0.15%Professional Trade Ideas - Newser
ARTV Technical Analysis & Stock Price Forecast - Intellectia AI
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
BZ2704 Forecast — Price Prediction for 2026. Should I Buy BZ2704? - Intellectia AI
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Monday - MarketBeat
ARTV SEC FilingsARTIVA BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
If You Invested $1,000 in ARTIVA BIOTHERAPEUTICS INC (ARTV) - Stock Titan
FFAIW Should I Buy - Intellectia AI
POWWP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LEGT Should I Buy - Intellectia AI
Market Rankings: Can PROP deliver consistent EPS growth2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Should I add Artiva Biotherapeutics Inc stock to my portfolio2026 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
02652 Should I Buy - Intellectia AI
TOLL Should I Buy - Intellectia AI
GRABW Should I Buy - Intellectia AI
Wedbush Maintains Artiva Biotherapeutics (ARTV) Outperform Recommendation - MSN
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest - MarketBeat
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies - The Globe and Mail
Research Analysts Issue Forecasts for ARTV Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Clinigence Holdings (NUTX) - The Globe and Mail
Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Outlook - Minichart
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts - TipRanks
ARTV: AlloNK shows promise in refractory RA as clinical and financial milestones approach in 2026 - TradingView
Artiva Biotherapeutics 10-K: Revenue $0.0M, Net Loss $(83.9)M — Cash $108.0M - TradingView
ARTV: 2025 net loss widened to $83.9M as R&D spending increased; cash runway extends into Q2 2027 - TradingView
Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 - Traders Union
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
Growth Value: Is Stantec Inc on track to beat earningsWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
What insider trading reveals about Artiva Biotherapeutics Inc. stock2026 Price Swings & Advanced Swing Trade Entry Plans - Naître et grandir
Dow Update: Does Artiva Biotherapeutics Inc have consistent dividend growthWeekly Gains Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - MarketBeat
Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer - BioSpace
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):